Table 1 Study characteristics
From: Cartilage evaluation by ultrasonography in patients with rheumatoid arthritis: a scoping review
Author | Year | Country | Study designs | Single or multicenter study | Participants | No. of parents | Age, yr (median) | Sex (%female) | Disease duration, yr (median) | Joints |
|---|---|---|---|---|---|---|---|---|---|---|
Aisen et al. [12] | 1984 | USA | D | S | RA + PsA/OA/others/healthy | 2 + 1/7/3/7 | 48/67/25/31 | — | — | Knee |
Iagnocco et al. [28] | 1992 | Italy | CS | S | RA/OA/healthy | 48/60/30 | 24–45/52–75/18–63 (range) | 63/55/53 | — | Knee |
Grassi et al. [18] | 1993 | Italy | CS | S | RA/healthy | 20/20 | 57/— | 70/— | 18.5/— | MCP 2 and 3 |
Østergaard et al. [19] | 1995 | Denmark | CS | S | RA/others/OA/healthy | 10/3/2/5 | 49 (RA + others)/53/29 | — | 4 (RA + others)/8/— | Knee |
Lund et al. [20] | 1995 | USA | CS | S | RA/healthy | 29/0 | 24–74/28–56 (range) | 90/50 | 0.5–2/— (range) | MCP 2–5, wrist |
Batalov et al. [13] | 2000 | Bulgaria | D | S | RA/OA/healthy | 30/14/14 | 36–57/36–73/25–37 (range) | — | — | Knee |
Möller et al. [29] | 2009 | Switzerland | CS | S | RA/OA/others/healthy | 48/18/24/34 | RA (early: 45, persistent: 57)/59/50/42 (median) | 75/89/63/68 | RA (early: 0.3, persistent: 8)/1/0/— (median) | MCP 2–5, PIP 2–5 |
Darweesh et al. [21] | 2010 | India | CS | S | RA/OA | 32/10 | 42/59 | 75/67 | 7.8/10.5 | Knee |
Sanja et al. [22] | 2010 | Serbia | CS | S | RA/DSD | 77/101 | 61/61 | 70/63 | 7.3/— | Shoulder |
Filippucci et al. [30] | 2010 | Italy | CS | S | RA | 20 | 51 | 80 | 8.7 | MCP 2 and 3 |
Riente et al. [14] | 2010 | Italy | CS | M | RA | 100 | 58 | 79 | 8.0 | Knee |
Yücesoy et al. [23] | 2011 | Turkey | CS | S | RA | 30 | 56 | 83 | — | Knee |
Di Geso et al. [15] | 2012 | Italy | CS | M | RA | 52 | 62 | 75 | 9.7 | Hip |
Pereira et al. [24] | 2014 | Brazil | CS | S | RA | 60 | 58 | — | 16.4 | MCP 1–5 |
Bisi et al. [25] | 2014 | Brazil | CS | S | RA | 60 | 58 | 78 | 10.0 | MCP 2 and 3 |
Mandl et al. [3] | 2015 | Austria | CS | M | RA/healthy (cadaver) | 35/5 | 63/78 | 83/100 | 10.6/— | MCP 2–5, PIP 2–5 |
Onodera et al. [31] | 2015 | Japan | CS | S | RA | 15 | 66 | 87 | — | MTP 2–5 |
Luz et al. [11] | 2016 | Brazil | L | S | RA | 48 | 48 | 100 | 0.6 | MCP 2 and 3 |
Mesci et al. [32] | 2016 | Turkey | CS | S | RA/healthy | 40/40 | 54/51 | 88/85 | 6/— (median) | Knee |
Sakthiswary et al. [33] | 2017 | Malaysia | CS | S | RA/healthy | 61/27 | 53/49 | 90/89 | 8.8/— | Knee |
Sarzi-Puttini et al. [10] | 2018 | Italy | I | M | RA | 66 | 53 | 82 | 1.5 (median) | MCP 2 and 3, most clinically involved MCP |
Hurnakova et al. [16] | 2019 | Italy | CS | M | RA/OA | 52/34 | 58/64 | 71/79 | 9/4.7 | MCP 2–5 |
Yang et al. [26] | 2019 | China | CS | S | RA/healthy | 53/30 | 42/42 | 83/77 | 0.9/— | MCP 1–5, PIP 1–5, wrist |
Mandl et al. [17] | 2019 | Austria | CS | M | RA | 6 | 64 | 67 | 15 | MCP 2–5, PIP 2–5 |
Abda et al. [27] | 2020 | Egypt | CS | S | RA | 100 | 45 | 88 | — | MCP 2 and 3 |
Ogura et al. [34] | 2021 | Italy | CS | S | RA/healthy | 103/42 | 65/63 (median) | 77/86 | 5.8/— (median) | MCP 2–5, PIP 2–5 |
Cipolletta et al. [35] | 2020 | Japan | CS | S | RA/healthy | 20/15 | 50/56 | 75/67 | 10.7/— | MCP 2–5 |
Cipolletta et al. [36] | 2022 | Italy | CS | S | RA/healthy | 51/40 | 51/49 | 73/73 | 5.8/— | MCP 2–5 |
Yildirim et al. [37] | 2022 | Turkey | CS | S | RA/healthy | 55/55 | 47/45 | 75/75 | 0.5/— | Knee, ankle |